• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Trends in Microbiology >Preclinical testing of new drugs for tuberculosis: current challenges
【24h】

Preclinical testing of new drugs for tuberculosis: current challenges

机译：结核病新药的临床前测试：当前的挑战

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The continuing global epidemic of tuberculosis, the increasing rate of multidrug resistant (MDR) tuberculosis and the more recent emergence of extensively drug resistant (XDR) tuberculosis are great causes for concern. A major international effort is currently underway to optimize current drug therapies and to discover new drugs that are active against these organisms. This effort has created a pipeline of new candidate drugs at various stages of preclinical and early clinical evaluations. Major challenges still exist, however, varying from the standardization and application of current animal models and their application to drug discovery and characterization to the fact that our knowledge about the basic biology of the MDR and XDR strains of Mycobacterium tuberculosis is minimal at best.
机译：持续的全球结核病流行，多药耐药性（MDR）结核病的发病率增加以及近期广泛耐药性（XDR）结核病的出现是引起人们关注的重要原因。国际上正在进行一项重大努力，以优化当前的药物疗法并发现对这些生物具有活性的新药。这项工作已经在临床前和早期临床评估的各个阶段创建了新的候选药物渠道。然而，主要挑战仍然存在，从当前动物模型的标准化和应用，其在药物发现和表征中的应用到我们对结核分枝杆菌MDR和XDR菌株基本生物学的了解至多，这一事实不尽相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号